Shares of Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) have received an average rating of “Hold” from the eight ratings firms that are currently covering the company. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $1.15.

TKAI has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Tokai Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Tuesday, November 8th. Stifel Nicolaus lowered shares of Tokai Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Wells Fargo & Co. lowered shares of Tokai Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 26th. BMO Capital Markets reissued a “market perform” rating and issued a $1.15 price objective (down previously from $1.70) on shares of Tokai Pharmaceuticals in a research report on Wednesday, August 24th. Finally, William Blair downgraded shares of Tokai Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 26th.

Tokai Pharmaceuticals (NASDAQ:TKAI) opened at 1.18 on Monday. Tokai Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $11.92. The stock’s 50 day moving average is $1.31 and its 200-day moving average is $3.37. The firm’s market cap is $26.72 million.

Several hedge funds have recently made changes to their positions in TKAI. Susquehanna International Group LLP increased its stake in shares of Tokai Pharmaceuticals by 622.5% in the third quarter. Susquehanna International Group LLP now owns 72,248 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 62,248 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Tokai Pharmaceuticals during the third quarter valued at approximately $150,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of Tokai Pharmaceuticals by 9.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 135,053 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 11,197 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Tokai Pharmaceuticals by 5.1% in the third quarter. JPMorgan Chase & Co. now owns 102,450 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 5,008 shares during the last quarter. Finally, Bridgeway Capital Management Inc. increased its stake in shares of Tokai Pharmaceuticals by 66.7% in the second quarter. Bridgeway Capital Management Inc. now owns 100,000 shares of the biopharmaceutical company’s stock valued at $551,000 after buying an additional 40,000 shares during the last quarter. 23.65% of the stock is owned by institutional investors and hedge funds.

Tokai Pharmaceuticals Company Profile

Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

5 Day Chart for NASDAQ:TKAI

Receive News & Stock Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.